Sarepta Shares Close at $17.82 Amid No Confirmation of Prasad’s Reappointment
Key Facts
Sarepta Therapeutics shares closed at $17.82 on November 6, 2026, compared with the previous session’s close of $17.57, according to the market data provided. This came as reports that Vinay Prasad had been reappointed as the FDA’s senior vaccines official could not be verified, and a premarket drop in the stock on the date of the report was also unconfirmed. Reliable information is therefore unavailable to link the share move to that administrative change. The November 6 close was above the November 5 close of $17.57. The share move followed the company’s announcement of third-quarter results on November 5, which showed a decline in total revenue compared with the same period a year earlier.
Sarepta’s total revenue was $381.4 million in the third quarter of 2026, versus $399.4 million in the same period of 2025, a decline of $18 million, the company said. It attributed the decrease primarily to lower Elevidys sales volume after an update to the treatment’s label restricted its use to patients able to walk. In contrast, the company said the revenue decline was partially offset by a $31.4 million increase in contract manufacturing revenue. That increase was tied to higher commercial Elevidys supply delivered by the company to Roche. This puts product performance at the center of the changes in quarterly revenue, between lower sales and increased contract manufacturing.
Net product revenue was about $323.8 million in the third quarter, according to the company’s filing with the U.S. Securities and Exchange Commission. That revenue included $240.3 million from PMO products and $83.5 million from Elevidys. In its financial guidance, the company raised the lower end of its 2026 net product revenue outlook by $50 million, to a range of $1.25 billion to $1.3 billion. It said strong performance from PMO products drove the increase in the lower end of the outlook. The guidance combines an improved full-year outlook with third-quarter indicators showing a year-over-year decline in total revenue.
For Elevidys, Sarepta expected fourth-quarter net product revenue to track at a level similar to the third quarter. The company noted that revenue from the one-time gene therapy is subject to natural variability. It also said multiple ascending-dose data for its SRP-1003 and SRP-1001 programs were expected in the fourth quarter of 2026. The company added that it was preparing to advance both programs into Phase 3 development. These timelines mark the main operational milestones the company cited after its third-quarter results.
Against the background of the Prasad report, Reuters said he left the FDA on July 30, 2025, only a few months after taking charge of the Center for Biologics Evaluation and Research. It added that he returned to his post at the agency’s request. The report of his reappointment could not be verified from a reliable open source as of the date of this report. Sarepta’s November 6 closing price and its quarterly results therefore remain the figures available for this coverage. The closing data alone do not establish a link between the share move and the report concerning Prasad.